{"name":"Lumen Therapeutics","slug":"lumen-therapeutics","ticker":"","exchange":"","domain":"","description":"Lumen Therapeutics is a biotechnology company focused on developing innovative treatments for patients with unmet medical needs. The company's lead candidate, Nona-L-arginine, has been discontinued, indicating a shift in their research and development strategy.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOUFNUZVk1S2tVM2xkSGZrbno4LXJUdU0xZU9leHpURnk0a1hNUFk3dnJkV0JSM0FpdThubkM0VTlTcTJ3VmhCZGNaeWYyUzItQXVJX25TM1dmY0phWjk2ZlE0dmRnN3NTR3VoWFd5dkRULUxqVlpxenhFUE12R2xXUDViQ2gyZHJZRGlybzVlRk5EUmhtb3ZVUE5wcy1DV3h2alJNdExKT2M4X1J0emdjcnRxcw?oc=5","date":"2026-04-08","type":"regulatory","source":"Eyes On Eyecare","summary":"i-Lumen Scientific earns FDA IDE clearance for dry AMD trial - Eyes On Eyecare","headline":"i-Lumen Scientific earns FDA IDE clearance for dry AMD trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQWXA4M0ljajFJQnZaT3gtYWlEZWMweF9NdVNmM3dYUnA4X2c0c1NaclFwQlIxOGJWQkEwSGFkTEhzeWVpT3NRQ0RQeVVhUTZhQk54N0RrZnNBSXdtS0tkdEFDbVJ0S3daR0hqYkl0eWpBcThGMVlhVWd6ZE94dmtnRDJ0bU1KaVpOTGUyXzhTRXlNMjJNbnJDOHYtUmd2NVNoak5GZWJQTlU5RlV5UkZkQjZ6OEhBcGpyUjhaUkNoQlZZSzZXRmJhaTUxMDhCWXNI?oc=5","date":"2026-02-23","type":"pipeline","source":"Citeline News & Insights","summary":"20 Voices: What Does 2026 Hold For Biopharma? - Citeline News & Insights","headline":"20 Voices: What Does 2026 Hold For Biopharma? - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9BdjR3eXRaTU41dGJfN0wxWHc3UmJyUGc5SkhwUXI5czB1T05fWFdGZG1VWFRGd0dGTW9BUXhMVkkzcVhXbHBha3VhTG1fbmlCbS0yc2ZJWExscnJ5VDYxR3NlM1NnOWtJLVgzbDY2LWFhQQ?oc=5","date":"2025-11-11","type":"pipeline","source":"Labiotech.eu","summary":"Seattle top biotechs 2025: the 9 companies you should now about - Labiotech.eu","headline":"Seattle top biotechs 2025: the 9 companies you should now about","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPaWg0cmpRMnYtb01iV0xKMGJBU0hVXzVoSHhoVWdLZjdqcGZpSnllSzItd1l4TTNCbmF2Q19Hd0FreUtTRHM2U19sZ2w4cjRUQ2tJbzUtSlJ1ZU1CeUd2WHgwOUNjbTVlaGY5QUJGU0p1bW5Lcm9ERlhoZURPakdDR3ZpeDZXTUtGRlpKbTF4Y1liQQ?oc=5","date":"2025-10-10","type":"pipeline","source":"Fierce Biotech","summary":"Former CBER chief Peter Marks leaps to Lilly—Chutes & Ladders - Fierce Biotech","headline":"Former CBER chief Peter Marks leaps to Lilly—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQMzVuQjlSSHJjeFFYRTF3WFJQM0RRVzJ4TTBreWk4UXNFZjdWTTdhM0hqNEJyY3VOaldwRmNFZG02NkJEaWVqREstbE83c0FLc1BES0N6OWctcmMybkFrTll5UFF2VHJFaGo5b0pNdzZjamhUY0l6RnFvQ20wenFkVFcza2pNTEtsVVhDNlJ0a2J1cWdZVEZCYmVYWGNvWkpPM19hejNOamZuVW5nM2ZxQUV4YmduMlh0Z3ZxX1p6Vmo?oc=5","date":"2025-10-08","type":"pipeline","source":"GeekWire","summary":"Fresh off $30M round, Seattle startup Lumen Bioscience adds Microsoft vet Jeff Raikes to board - GeekWire","headline":"Fresh off $30M round, Seattle startup Lumen Bioscience adds Microsoft vet Jeff Raikes to board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxNQnZaOHUwbWFabkV0RFAwSE4tQjNxVG5pNnFGWjFiNHlnbGI5SjBUc1pJblMydnpYN3NoV25ZcGlpdmdLM25nM0JHZVB1dnNGOGpvQjlhZ1Z3SFdFQjFPYWk3TnItRXJHeXRpTXctS1Q3RG5KVjF5MGVWX1d6eXM4RE5leUVMY0MtWUtoV0ZWeHZTb0UwZUM4bG95RkFUS25NWHdSVEwwRVF1OHNocUxiQTJvandOZ0J5aHpjVWlVRGpmYXNnbGtEcUZUQXJnN1Jmd0QxTjlvSFJKS21OY2djaVRhR2R2bnFQRHNBXzB4eDhTX3JNdnM5MWYzNk1Gc3p2WXcwakpNZlAzT3IyZzZaRjFhRG9MUGo5ZnNKODhVNWI4UXdqYV9JTTMtSDQtVEJKWHBvRm5ldDlWczFxWEdYaw?oc=5","date":"2025-09-02","type":"pipeline","source":"PR Newswire UK","summary":"Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in the 7MM during the Forecast Period (2025-2034) - PR Newswire UK","headline":"Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQWUoxZzBKRFFjR3hfeDRfMDBwMUoyV1JrOXZSVEhXSEtpazdJSXQzcU92LVp6MGZTZXFjZUxNbnpkbTRPcTVrTU1aMXZES3FUbk4tb3c4OVEyT3I0MHRXUFQtX1dNQy02UXBPMDN0VzNTUlB1QW5fbjlxX3h3NXVJT3Y0WS1sSGdL?oc=5","date":"2024-05-04","type":"pipeline","source":"OpenSecrets","summary":"Pharmaceuticals/Health Products Lobbying Profile - OpenSecrets","headline":"Pharmaceuticals/Health Products Lobbying Profile","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQbVRSU3VRLXdBeElySTl5eFAzbW1GZnZZTzhKdUJCc0ZJN1hnVDkzbjF4czRtYTAxMG56OThJbTIyT252ME5qOFZIQnIwdEVXWWZ6Ti1KTk5yVkVFUnNCU0RrVms2SkVZNW5sVGhBVGVER0hnanV1djllWTNZRlNqMnlDRUNOaFBlSHd2ajVLdHBCbWlHZl9LRQ?oc=5","date":"2024-01-19","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Lumen Bioscience pursues oral biologic to prevent recurrent C. diff - drugdiscoverytrends.com","headline":"Lumen Bioscience pursues oral biologic to prevent recurrent C. diff","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQRVU3ek5ocnlodlh6a0tsV3lBU1RCRDFPOEpROS1DenBXT1JqNFVTTTljWTZlTWVhZldNUGRnNjFDcHlYY0pNeE1OcDl6VUo3dzVibng4V3c5Z0NvRVV1T1pXdGY3Zm1DWHFTLXBNOGRIYWNPQ0gyemNSWmwzbm5hUlYzMGpiWE1XX0xOTmhCdmpqWmg3S2NQZ2Y5b0pFV2thWVpxNVFNX3YxcG5OQ0o3TFEzbndHSXd2dzhnR3psdncyLWpWRGVLR3FudmdCazlseDBlWjA5dEpnTk5ocDlrZVltelZqQ1VB?oc=5","date":"2023-10-17","type":"trial","source":"PR Newswire","summary":"Lumen Bioscience awarded $16.2 million in DoD funding to advance LMN-201 through late-stage trials - PR Newswire","headline":"Lumen Bioscience awarded $16.2 million in DoD funding to advance LMN-201 through late-stage trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQTmp2NnN2aWJCTkMzamF1UXh6VVFDRENfU2E2WjJEQldDaldqc1VBcUtOaTNBRkgyQnNJa1dqZ05TOWJtRzR0T3hRV2I3VEE1Wk5KNDJIWi1YNVBnVWhFNEk0a0t2NnZTWnktaU9Lbm9hWjA4R3JRWFJmNTVYaGZxc3VvOXA5VEVlYkVGbGp6al9xdTZrdmIxQVZaNk1JaFNXQXZxbTZnb3ZNRmgyUFhueE9OT2FlUjJHczRQWA?oc=5","date":"2022-03-24","type":"pipeline","source":"European Pharmaceutical Review","summary":"Lumen publishes details of spirulina biomanufacturing platform - European Pharmaceutical Review","headline":"Lumen publishes details of spirulina biomanufacturing platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1nOTgxMzhhXy1MbTB6T2JxMk1ONVdNdUhJQmRfNHhXbVJZaEk1UXltczFsSER0ZFROLXZsTUFQWUh6cFZZUTlobXRXUGVEQ1hyXy1QSExHbG1ncHlKQkRz?oc=5","date":"2022-03-21","type":"pipeline","source":"Nature","summary":"Development of spirulina for the manufacture and oral delivery of protein therapeutics - Nature","headline":"Development of spirulina for the manufacture and oral delivery of protein therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOSjFfTnlwS3BPUUh0NkFZR1d1Q09XVUFlN3B5aVJXb1lNUVVhMnduQUdYQ0V2VDJtZE5lcm1lNVRsdWRSc1REaDNJZmV3RVg1ZkxTeTA0WXlVckN1eFJNODRxS0Jtb2Z5RlJLSUZyVFhRR0E2U0dQUG1tZVl1SDJBc19OUERTTFk?oc=5","date":"2020-09-10","type":"pipeline","source":"Pharmaceutical Technology","summary":"Powering biologics development with spirulina: Lumen closes $16m Series B - Pharmaceutical Technology","headline":"Powering biologics development with spirulina: Lumen closes $16m Series B","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}